Infectious Diseases News and Research

RSS

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa.

18 Oct 2010

GeoVax Labs contributes article for HIV vaccine

Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).

18 Oct 2010

OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented in an oral presentation at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, results showing that hemoglobin (Hb) measurements obtained by its NBM 200MP, a non-invasive Hb measurement system, showed accurate performance during hemorrhage conditions compared with invasive point of care (POC) devices.

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Phase III study influences WHO to change guidelines for HIV-infected women receiving nevirapine

Findings from a study, which appear in the Oct. 14, 2010 New England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies.

18 Oct 2010

IDRI's TB vaccine protects against drug-resistant tuberculosis

The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

18 Oct 2010

Three West African countries set to roll out new meningitis vaccine

A new vaccine for meningitis, MenAfriVac, offers hope of an escape from one of the world's deadliest, most disabling and infectious diseases, the BBC writes. The vaccine was developed by non-governmental organization PATH in partnership with the WHO and created specifically for Africa.

18 Oct 2010

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

18 Oct 2010

Oseltamivir reduces mortality in influenza A/H5N1 patients

A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness.

15 Oct 2010

Crosstex International introduces customized surgical masks

Cantel Medical Corp., announced today the launch of a new, unique design of medical face masks - the SecureFit™ series by Crosstex International, a Cantel subsidiary and a leading U.S. manufacturer of medical face masks. The SecureFit™ series of masks addresses scientific research that points to poorly fitting masks as a major hindrance to their effectiveness.

15 Oct 2010

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

NIH awards two new grants to develop Avidocin platform

AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.

15 Oct 2010

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

IRIS International, Inc. a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Iris Molecular Diagnostics (IMD)has been granted Patent No. EP1842226B1 by the European Patent Office (EPO) covering aspects of IMD's NADiA ultra-sensitive protein detection and cell phenotyping platform, which can detect proteins in the femtogram (1 quadrillionth) per milliter range and phenotype single cells.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

NIH awards grant to Bavarian to advance early research in filoviruses

Bavarian Nordic A/S announced today that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus).

14 Oct 2010

Detect-Ready MRSA assay receives first independent validation

Molecular Detection Inc. a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK.

13 Oct 2010

Medical Exchange announces next generation of continuing medical education events

Medical Exchange, an innovative provider of medical education solutions for the health care industry, today announced the next generation of continuing medical education events with the launch of collaborativeCARE Conference (C3).

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Infectious Diseases News and Research

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

GeoVax Labs contributes article for HIV vaccine

OrSense's NBM 200MP non-invasive Hb measurement system more accurate than invasive POC devices

NanoViricides' President delivers speech at ASNM Second Annual Conference

Phase III study influences WHO to change guidelines for HIV-infected women receiving nevirapine

IDRI's TB vaccine protects against drug-resistant tuberculosis

Three West African countries set to roll out new meningitis vaccine

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Oseltamivir reduces mortality in influenza A/H5N1 patients

Crosstex International introduces customized surgical masks

NovaBay to present two poster presentations at IDSA Annual Meeting

NIH awards two new grants to develop Avidocin platform

IMD receives EPO patent for NADiA ultra-sensitive protein detection and cell phenotyping platform

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

NIH awards grant to Bavarian to advance early research in filoviruses

Detect-Ready MRSA assay receives first independent validation

Medical Exchange announces next generation of continuing medical education events

New evidence supports possible link between XMRV and prostate cancer

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

eBook: Advancing infectious disease vaccine development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News